ICI118551   Click here for help

GtoPdb Ligand ID: 543

Synonyms: ICI 118551 | ICI-118,551 | ICI-118551
PDB Ligand
Compound class: Synthetic organic
Comment: ICI-118,551 is a β-adrenoceptor modulator [16]. This S,S-enantiomer is the most potent optical isomer with regards to activity as a β2-selective β-blocker.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 41.49
Molecular weight 277.2
XLogP 3.34
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(N[C@H]([C@@H](COc1ccc(c2c1CCC2)C)O)C)C
Isomeric SMILES Cc1c2CCCc2c(cc1)OC[C@H]([C@H](C)NC(C)C)O
InChI InChI=1S/C17H27NO2/c1-11(2)18-13(4)16(19)10-20-17-9-8-12(3)14-6-5-7-15(14)17/h8-9,11,13,16,18-19H,5-7,10H2,1-4H3/t13-,16+/m0/s1
InChI Key VFIDUCMKNJIJTO-XJKSGUPXSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor.
J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
4. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
5. Baker JG. (2010)
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Br J Pharmacol, 160 (5): 1048-61. [PMID:20590599]
6. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
7. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.
ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874]
8. Baker JG, Gardiner SM, Woolard J, Fromont C, Jadhav GP, Mistry SN, Thompson KSJ, Kellam B, Hill SJ, Fischer PM. (2017)
Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.
FASEB J, 31 (7): 3150-3166. [PMID:28400472]
9. Baker JG, Hall IP, Hill SJ. (2002)
Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Br J Pharmacol, 137 (3): 400-8. [PMID:12237261]
10. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]
11. Baker JG, Hall IP, Hill SJ. (2003)
Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Mol Pharmacol, 64 (3): 679-88. [PMID:12920204]
12. Baker JG, Kemp P, March J, Fretwell L, Hill SJ, Gardiner SM. (2011)
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
FASEB J, 25 (12): 4486-97. [PMID:21865315]
13. Baker JG, Lim VJY, Proudman RGW, Giese FNZ, Kolb P. (2025)
Predicting compounds that interact with the 2 known agonist-induced conformations of the human β1-adrenoceptor.
Mol Pharmacol, 107 (11): 100081. [PMID:41289653]
14. Baker JG, Proudman RG, Hill SJ. (2013)
Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.
PLoS One, 8 (11): e77582. [PMID:24250787]
15. Baker JG, Proudman RG, Hill SJ. (2014)
Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.
Mol Pharmacol, 85 (5): 811-29. [PMID:24608857]
16. Baker JR, Hothersall JD, Fitzmaurice RJ, Tucknott M, Vinter A, Tinker A, Caddick S. (2010)
An efficient asymmetric synthesis of the potent beta-blocker ICI-118,551 allows the determination of enantiomer dependency on biological activity.
Chem Commun (Camb), 46 (22): 3953-4. [PMID:20431838]
17. Blin N, Nahmias C, Drumare MF, Strosberg AD. (1994)
Mediation of most atypical effects by species homologues of the beta 3-adrenoceptor.
Br J Pharmacol, 112 (3): 911-9. [PMID:7921620]
18. Buxton BF, Jones CR, Molenaar P, Summers RJ. (1987)
Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues.
Br J Pharmacol, 92 (2): 299-310. [PMID:2823947]
19. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. (2004)
Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Naunyn Schmiedebergs Arch Pharmacol, 369 (2): 151-9. [PMID:14730417]
20. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. (1999)
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Eur J Pharmacol, 367 (2-3): 431-5. [PMID:10079020]
21. Proudman RGW, Baker JG. (2025)
A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β2-Agonists Used for Asthma and COPD.
Pharmacol Res Perspect, 13 (5): e70154. [PMID:40887869]
22. Sato T, Baker J, Warne T, Brown GA, Leslie AG, Congreve M, Tate CG. (2015)
Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor.
Mol Pharmacol, 88 (6): 1024-34. [PMID:26385885]
23. Strosberg AD. (1997)
Structure and function of the beta 3-adrenergic receptor.
Annu Rev Pharmacol Toxicol, 37: 421-50. [PMID:9131260]
24. Tricomi J, Landini L, Nieddu V, Cavallaro U, Baker JG, Papakyriakou A, Richichi B. (2023)
Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships.
Eur J Med Chem, 246: 114961. [PMID:36495629]
25. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. (2013)
The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors.
Eur J Pharmacol, 720 (1-3): 124-30. [PMID:24183974]